Global Pfizer CEO Albert Bourla is the pharma executive with the biggest impact on social media, according to a new study. While busy industry leaders may not currently place social media engagement at the top of their priority lists, the study – published by specialist digital insights consultancy, Creation Healthcare –…
Global The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. Last year, orphan drugs accounted for more than a third of Europe’s new drug approvals, and the number of gene…
Global Ever since Novo Nordisk launched Wegovy two years ago, the company has struggled to meet the huge demand for its breakthrough weight loss drug and is yet to make it available in a larger range of markets. Following a recent launch in Germany, Novo Nordisk CEO Lars Fruergaard Jørgensen makes…
Global 2023 got off to a good start for Boehringer Ingelheim’s human pharma division. Not only has the year begun with substantial sales growth thanks to the German firm’s diabetes and heart failure drug, Jardiance, the company is also advancing on a number of other fronts. While Jardiance is expected to…
Global Regular contributor Brendan Shaw* casts his eye over the recently announced 2023 WHO Essential Medicines List, how it reflects growing pharmaceutical innovation, and why maintaining a ‘seat at the table’ for the pharma industry in these discussions will be crucial to meeting global healthcare access goals. Recently, the World…
Global The Alliance for Regenerative Medicine (ARM) brands itself as the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. ARM’s latest sector snapshot details the cell and gene therapy approvals list for 2022, as well as the number of…
Global The world’s top 10 medical technology companies for 2022 according to Medical Product Outsourcing (MPO). Abbott leads the way, followed by Medtronic, J&J, and Siemens Healthineers. Recent PharmaBoardroom interviews with some of these companies’ leading executives include Hugo F. Villegas, SVP & President, Canada & Latin America at Medtronic, Eman…
Global Speaking as GM and head of the Middle East, Turkey, and Africa region, Andrew Bird, who has since become Acino’s Interim Chief Executive Officer, discusses the Swiss company’s “being global but acting local” approach to emerging markets and outlines the importance of the META region, which accounts for 35 percent…
Global Smart manufacturing has become a key component of today’s industrial evolution and unlocked unprecedented efficiencies and quality enhancements. Smart Manufacturing expert Eric Whitley outlines the specific benefits of smart manufacturing for the pharmaceutical industry, illustrating these benefits with industry case studies. Smart manufacturing has entered the world of modern…
Global Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such tools in other aspects of the pharma value chain, Rauland and Kishore speculate how they might come to revolutionise pricing…
Global Eli Lilly recently revealed more than promising clinical trial results for its Alzheimer’s candidate, donanemab, showing that the drug slows Alzheimer’s by as much as 60 percent in mild cases. While safety concerns about the drug remain, Lilly is hoping for an FDA approval by the end of the year.…
Global Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new CEO leadership team, with appointees from Pfizer, Roche and Daiichi Sankyo. As the industry’s biggest global trade group that…
See our Cookie Privacy Policy Here